Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021
Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 -- Inivata, a leader in liquid biopsy, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place on 10-15 April 2021. Data on the Company’s InVisionFirst-Lung liquid biopsy test will also be presented.
Two posters will highlight new data in support of RaDaR as a highly sensitive, personalized assay for the detection of residual disease and recurrence. The assay allows both detection of residual disease following curative intent or definitive treatment and early detection of relapse. Tracking a set of up to 48 tumorspecific variants in a patient, RaDaR is built on Inivata’s proven InVision® liquid biopsy platform technology. A third poster will also be presented showcasing new data on InVisionFirst-Lung, Inivata’s highly sensitive 37 gene liquid biopsy test relevant to the care of patients with advanced NSCLC.
Abstracts are available now on the AACR website. The accompanying posters will be available to view during the conference via the AACR e-poster site, together with audio descriptions.
Clive Morris, CEO of Inivata, commented: “Personalized liquid biopsy assays have the potential to transform current cancer treatment regimens by detecting recurrence earlier. We look forward to sharing this new data on RaDaR, which will highlight the continued clinical evidence in support of our assay across different solid tumor types. We will also be presenting new data on InVisionFirst-Lung that could help guide precision medicine.”
Details of the abstracts are as follows:
Title: Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach Session: PO.CL11.04 - Liquid Biopsies: Circulating DNA Timing: Saturday, 10 April at 8:30 AM – 12:00 PM ET Abstract No: #536 Link to abstract: https://www.abstractsonline.com/pp8/#!/9325/presentation/1630
Title: Personalized circulating tumor DNA analysis in head and neck squamous cell carcinoma – preliminary results of the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study Session: PO.CL11.04 - Liquid Biopsies: Circulating DNA Timing: Saturday, 10 April at 8:30 AM – 12:00 PM ET Abstract No: #553 Link to abstract: https://www.abstractsonline.com/pp8/#!/9325/presentation/1650
Title: Resistance Mechanism to BRAF inhibition Identified by Single Circulating Tumor Cell and Cell-free tumor DNA molecular profiling in BRAF-mutant Non-Small-Cell Lung Cancer Session: PO.CL11.04 - Liquid Biopsies: Circulating DNA Timing: Saturday, 10 April at 8:30 AM – 12:00 PM ET Abstract No: #598 Link to abstract: https://www.abstractsonline.com/pp8/#!/9325/presentation/1695